Passionate about progress
Passionate about progress
Passionate about progress

 

At SCILEX, we’re excited to develop and commercialize innovative pain management solutions to help improve patient care. Learn more about what’s going on at SCILEX.
 

Investor relations

SCILEX Pharmaceuticals specializes in
manufacturing branded treatments to manage acute and chronic pain.

CONTACTS

SCILEX Pharmaceuticals, Inc.
(844) SCILEX1
WPedranti@scilexpharma.com

SCILEX news

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

SAN DIEGO, September 19, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Scilex expects commercial availability of ZTlido through wholesale distribution in …

Upcoming events

We’re keeping busy at SCILEX. See where we’ll be next.

Cultivating strong collaborations
Cultivating strong collaborations
Cultivating strong collaborations

Current partnerships

Strong relationships yield promising results. That’s why we’ve cultivated partnerships with some of the best minds in the business. As part of our strategy, SCILEX calls on industry leaders to assist the management team in innovating, manufacturing, developing, marketing, and selling novel products and technologies. Here’s just a sample of the notable partners across all sectors of the pharmaceutical industry with whom we collaborate.

  • Beckloff Associates Cardinal Health
    cGMP Regulatory
  • Clinipace Worldwide
    CRO, Regulatory
  • Foley & Lardner
    FDA Counsel
  • ITOCHU CHEMICAL FRONTIER Corporation
    ICF, Tokyo, Japan
  • Real Regulatory
    EU Regulatory
X

Share This Page

XS SM MD LG XL